A Phase 2 interventional study of AST-120 and lactulose in Hepatic Encephalopathy, sponsored by Ocera Therapeutics. Completed at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-05-30.
Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Hepatic Encephalopathy with a site in United States — 9 open to participants now, 13 under way, 1 of them phase 3. Hepatic Encephalopathy · United States.
Among the 70 studies in Hepatic Encephalopathy with a site in United States, this one is the 28th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2007, is one of 18 in phase 2, and was the 6th registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →9 of the 70 studies in Hepatic Encephalopathy with a site in United States are open now. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–99
The Cleveland Clinic · Sites in United States
Ages 18–75
Prof. Valérie Mc Lin · Sites in United States, Australia, Belgium and 13 more countries
Ages 1 days+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 9 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 39 across the 58 interventional studies, 38 across the 12 observational. Of the 48 that completed or were terminated, 19 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ocera Therapeutics, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Ocera Therapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.
Keenova Therapeutics plc has 5 studies filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
6 of the studies in Hepatic Encephalopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03420482Massachusetts General HospitalFecal Microbiota Transplant as Treatment of Hepatic Encephalopathy | 2026-12-31 |
| NCT07046429Weill Medical College of Cornell UniversityAffect of Melatonin on Sleep and Cognition in Cirrhosis | 2026-12-31 |
| NCT06425380Mayo ClinicPilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy | 2027-01-28 |
| NCT04096014The Cleveland ClinicLate Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy | 2027-06-30 |
| NCT07168395University of California, Los AngelesPre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Hepatic Encephalopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 compared to lactulose in patients with mild hepatic encephalopathy.
This is a multi-center, open-label, four week trial comparing AST-120 to lactulose in patients with mild (Stage 1-2) hepatic encephalopathy.
Patients will be randomized into two groups:
Patients meeting the inclusion criteria will take either AST-120 or lactulose for 4 weeks (28 days). AST-120 will be distributed in 2 gram sachets to be taken four times daily. Lactulose will be taken in the same formulation, at the same dose and frequency as previously prescribed for the individual patient.
Lactulose naïve patients who are randomized to lactulose will receive an initial dose of 30cc twice a day. The dose should be titrated at the discretion of the investigator until the patient is experiencing 2-3 soft stools per day.
Patients randomized to AST-120 will receive 2 grams four times a day for the duration of the study. Titration of AST-120 will NOT be allowed.
Patients will be evaluated throughout the study for efficacy and safety. A follow-up visit will be scheduled 1 week after the end of the 4 week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Patients already on lactulose and randomized to -120 will stop taking lactulose on the day they begin taking AST-120.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lactulose
Drug: AST-120
Change in Westhaven Scale
Time frame: 4 weeks
Efficacy: Change in Hepatic Encephalopathy Scoring Algorithm (HESA)
Time frame: 4 weeks
Efficacy: Reduction of venous ammonia levels
Time frame: 4 weeks
Efficacy: Serum bile acids and amino acid profile
Time frame: 4 weeks
Efficacy: Reduction in itching (visual analog scale)
Time frame: 4 weeks
Efficacy: Presence or absence of asterixis
Time frame: 4 weeks
Safety: Clinical laboratory tests
Time frame: 4 weeks
Safety: Physical examination, vital signs (blood pressure, heart rate, respiration rate, body temperature)
Time frame: 4 weeks
The record gives a start of Sep 2007, a primary completion of Mar 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AST 120 · Charcoal